BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

South Korea’s Lunit AI Proven to Enhance Breast Cancer Detection in Landmark Multicenter Study

Lunit, a global leader in AI-powered cancer diagnostics, has announced groundbreaking results from the world’s first large-scale, multicenter, prospe...

March 11, 2025 | News

Everest Medicines Doses First Patient with AI-Driven Personalized mRNA Cancer Vaccine EVM16 in Landmark Clinical Trial

The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoan...

March 07, 2025 | News

CStone Pharmaceuticals Advances CS5001 with Phase Ib Trial Application in Australia for First-Line DLBCL Treatment

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape ...

March 06, 2025 | News

CStone Pharmaceuticals Doses First Patient in Global Phase I Trial of Trispecific Antibody CS2009

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therap...

March 05, 2025 | News

Daiichi Sankyo and AstraZeneca’s ENHERTU Recommended for EU Approval for HER2 Low and HER2 Ultralow Metastatic Breast Cancer

Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in th...

March 03, 2025 | News

China Fapon Biopharma secures US FDA IND approval for FP008 a first-in-class immunocytokine for resistant solid tumors

Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce that the U.S. Food and Drug Administr...

March 03, 2025 | News

Akeso Enrolls First Patient in Phase I Trial for HER3-Targeting ADC AK138D1 in Australia

Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in...

February 28, 2025 | News

Akeso Begins Phase III Trial of Ivonescimab for First-Line Treatment of Advanced Triple-Negative Breast Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, ran...

February 24, 2025 | News

Harbour BioMed and Insilico Medicine Partner to Accelerate AI-Driven Antibody Discovery

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on...

February 21, 2025 | News

Syensqo and Emulseo Partner to Advance Microfluidic Innovations in Healthcare

Syensqo, a leading specialty chemicals company, is pleased to announce a strategic partnership with Emulseo, a French company specialized in formulations f...

February 21, 2025 | News

South Korea’s Brexogen Out-Licenses BxC-I17e to BMI Korea in Landmark Exosome Therapeutics Deal

Out-licenses BxC-I17e, Exosome-Based Therapeutics for New IndicationsKRW 3 Billion Non-Refundable Upfront Payment + Milestone Payments + Double-Digit ...

February 20, 2025 | News

Bambusa Therapeutics Closes $90 Million Series A to Advance Bispecific Antibody Pipeline for Immunological and Inflammatory Disorders

Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, anno...

February 17, 2025 | News

Alphamab Oncology Doses First Patient in Phase III Study of Anti-HER2 ADC JSKN003 for Platinum-Resistant Ovarian Cancer

Alphamab Oncology announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparat...

February 14, 2025 | News

Lion TCR Secures FDA Clearance for Phase 2 Trial of Pioneering mRNA TCR-T Therapy for Liver Cancer

Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug A...

February 12, 2025 | News

Stay Connected